Navigation Links
HUYA Bioscience Int'l Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
Date:6/17/2008

nic arrhythmia.

Most existing marketed and development-stage anti-arrhythmics have been associated with adverse events such as Torsade de Pointes (TdP - sudden death) or appreciable QTc prolongation (a risk factor for sudden death) in Phase I or preclinical studies. As noted above, in the preclinical studies and the three Phase I studies completed in China, HBI-3000 was well tolerated.

Atrial Fibrillation (AF) is a serious type of arrhythmia found in approximately 2.2 million Americans and about 15 percent of strokes occur in people with AF(1). Ventricular Arrhythmia (VA), a severely abnormal heart rhythm, will cause death unless treated immediately. Ventricular fibrillation (VF), a type of arrhythmia, is responsible for 75 to 85 percent of sudden deaths in persons with heart problems(2).

Currently, anti-arrhythmic drugs are commonly used to treat patients with AF and VA, though in treating patients with VA, most anti-arrhythmics have failed to demonstrate a survival advantage. In some cases they may also carry safety risks, including sudden death. Pre-clinical data developed by HUYA and its Chinese partner, along with the Chinese clinical trial data are encouraging to suggest that HBI-3000 may have a useful role in the treatment of ventricular arrhythmias.

In the United States, HBI-3000 is initially being developed and investigated for use as IV treatment of atrial fibrillation with clinical trials expected to begin in early 2009. "This is a significant area of medicine for which providers need more options to treat patients," continued Gingras. "Researchers in China are developing promising compounds that would fulfill these and other unmet medical needs in the U.S. As we prepare to assemble the data and submit our IND to initiate the Phase I trials, we'll continue to leverage our collaboration and expertise in China and the U.S. It's exciting to think of the amount of time and funding that could be saved by optimizing and streamlining
'/>"/>

SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
2. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
3. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
6. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
7. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Research and Markets ... of the "Global Gynecological Devices Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... wide categories based on their operations. These ... different gynecological conditions that affect the female ...
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Inc. (NASDAQ: DCTH ) announced today that management ... Conference on Tuesday, August 16, 2011 at 2:25 P.M. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. Delcath will offer a live audio webcast of ...
... 10, 2011 Leading events organizers UBM Canon ... (LSE: UBM), today announced a virtual conference event which will examine ... chain, counterfeit drugs. Titled ,Pharmaceutical Track & Trace Authentication: The Fight ... from 6:00 to 14:00 New York time, 12:00 to 20:00 Paris ...
Cached Medicine Technology:Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 3UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 2UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 3
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- The U.S. Food and Drug ... Thursday. Trulicity is part of a class of once-a-week injectable ... type 2 diabetes. "Trulicity is a new treatment ... treatment regimens to control blood sugar levels in the overall ... of the FDA,s Office of Drug Evaluation II, said in ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- More states are ... medication epinephrine to use for any child having a ... treatment for "anaphylaxis," an allergic reaction that can lead ... blood pressure and even death. In people ... or tree nuts, insect venom or certain drugs, anaphylaxis ...
(Date:9/19/2014)... 19, 2014 Top 10 Best ... announced that HostGator.com, GoDaddy and Bluehost are among ... companies are the most recommended suppliers for webmasters ... to buy high quality Linux hosting (including VPS ... is one of many top hosting companies that ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:A better way to track emerging cell therapies using MRIs 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2
... REMIND LAWMAKERS CALIFORNIA PREMIUMS ARE 17 PERCENT ... ... At the Assembly,Health Committee,s hearing on Governor Arnold Schwarzenegger,s health ... National Association of Insurance and Financial Advisors-California,(NAIFA-California) urged lawmakers to ...
... 31 Conseco, Inc. (NYSE:,CNO) today reported results for ... reflect a number of significant events, as,progress on our ... increasingly evident," CEO Jim Prieur said. "We saw continued,strong ... businesses, while,Conseco Insurance Group, even with a decline in ...
... Effective ... Alternatives, LOS ... thinking about health and medicine over the past few years as ... As concerns grow regarding conventional, over-the-counter,medicine, Hyland,s homeopathic medicines offer a ...
... Dr. James M. Farrell, a,doctor of chiropractic practicing ... Chiropractic Association (CCA). He was nominated,and chosen by his ... the CCA since 1992, Dr. Farrell has been extremely ... a committee chair, board member,and executive board member prior ...
... Today researchers report a newly identified genetic ... cancer in African American men. This study, which ... prostate cancer in high-risk populations, is published online in ... cancer is the second leading cause of cancer death ...
... feline DNA could help humans, too, scientists say , WEDNESDAY, ... of the domestic cat ( Felis catus ), an advance ... pets and provide an excellent model for human disease. , ... traced back several generations to Sweden, was the subject of ...
Cached Medicine News:Health News:Health Insurance Agents Warn Against Imposing a 'Health Care Reform' Tax in California 2Health News:Health Insurance Agents Warn Against Imposing a 'Health Care Reform' Tax in California 3Health News:Conseco Reports Third Quarter Results 2Health News:Conseco Reports Third Quarter Results 3Health News:Conseco Reports Third Quarter Results 4Health News:Conseco Reports Third Quarter Results 5Health News:Conseco Reports Third Quarter Results 6Health News:Conseco Reports Third Quarter Results 7Health News:Conseco Reports Third Quarter Results 8Health News:Conseco Reports Third Quarter Results 9Health News:Conseco Reports Third Quarter Results 10Health News:Conseco Reports Third Quarter Results 11Health News:Conseco Reports Third Quarter Results 12Health News:Conseco Reports Third Quarter Results 13Health News:Conseco Reports Third Quarter Results 14Health News:Conseco Reports Third Quarter Results 15Health News:Conseco Reports Third Quarter Results 16Health News:Conseco Reports Third Quarter Results 17Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:Golden Doctor of Chiropractic Elected President of the Colorado Chiropractic Association 2Health News:Scientists discover genetic variant associated with prostate cancer in African Americans 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e...
The Livewire cannulator offers improved access to the coronary sinus by combining the ergonomic Livewire steering mechanism with numerous specialized features....
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
Medicine Products: